Publications

At Bayer, we are working in collaboration with the leading scientific, academic, and community partners to improve our understanding of hemophilia A.

We invite you to explore Bayer-supported publications. This library is not intended to serve as a comprehensive repository of all publications. Publications not supported by Bayer are not included. Access to the full text of publications may depend on journal access rights.

To help narrow down your search, choose the relevant tags and click Apply. Selecting multiple tags will narrow your results.

Last updated May 22, 2024.

Types of Enhancements Available

Plain Language Summary

Infographic

Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12-<18 years at enrolment into PROTECT VIII

Reding MT, et al. Acta Haematol. 2024. Online ahead of print

Reding MT,

READ

Canadian clinical experience on switching from standard half-life rFVIII, octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Matino D, et al. Haemophilia. 2024. Mar;30(2):345-354

Matino D,

READ

Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study

Holme PA, et al. Haemophilia. 2024. Online ahead of print

Holme PA,

READ

Association of patient, treatment and disease characteristics with patient-reported outcomes: results of the ECHO Registry

Hay C, et al. Haemophilia. 2024; 30(1):106-115

Hay C,

READ

Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data

Nagao A, et al. Haemophilia. 2023;29(6):1519-1528

Nagao A,

READ

Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

Reding MT, et al. Eur J Haematol. 2023. Online ahead of print

Reding MT,

READ

Damoctocog alfa pegol for hemophilia A prophylaxis: an Italian multicenter survey

Zanon E, et al. Pharmaceuticals. 2023;16(9):1195

Zanon E,

READ

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Kenet G, et al. J Blood Med. 2023; 14:379-388

Kenet G,

READ

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Reding MT, et al. Ther Adv Hematol. 2023;14:20406207231166779

Reding MT,

READ

Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort

Fischer K, et al. J Thromb Haemost. 2023;21(3):700-703

Fischer K,

READ

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Site last updated 06/2024

Welcome to Bayer US Medical Affairs

Publications

Publications

Types of Enhancements Available

Long-term efficacy and safety of damoctocog alfa pegol prophylaxis in patients with haemophilia A aged 12-<18 years at enrolment into PROTECT VIII

Canadian clinical experience on switching from standard half-life rFVIII, octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada

Safety and efficacy of damoctocog alfa pegol prophylaxis in patients with severe haemophilia A: Results of an interventional, post-marketing study

Association of patient, treatment and disease characteristics with patient-reported outcomes: results of the ECHO Registry

Haemophilia and cardiovascular disease in Japan: Low incidence rates from ADVANCE Japan baseline data

Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A

Damoctocog alfa pegol for hemophilia A prophylaxis: an Italian multicenter survey

Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

Efficacy and safety of damoctocog alfa pegol prophylaxis in patients ⩾40 years with severe haemophilia A and comorbidities: post hoc analysis from the PROTECT VIII study

Different inhibitor incidence for individual factor VIII concentrates in 1076 previously untreated patients with severe hemophilia A: data from the PedNet cohort